Utpal Koppikar
Director/Board Member bei C4 THERAPEUTICS, INC.
Vermögen: 172 592 $ am 31.03.2024
Profil
Utpal Koppikar is an Independent Director at C4 Therapeutics, Inc. He previously worked as a Director at Flexion Therapeutics, Inc. and as Vice President-Corporate & Operations Finance at Gilead Sciences, Inc. He is also the Chief Financial Officer & Senior Vice President at Atara Biotherapeutics, Inc. Mr. Koppikar holds a graduate degree from Stanford University, an undergraduate degree from the University of Maryland, and an MBA from UCLA Anderson School of Management.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 02.03.2023 | 181 978 ( 0,14% ) | 126 293 $ | 31.03.2024 | |
C4 THERAPEUTICS, INC.
0,01% | 15.06.2023 | 5 667 ( 0,01% ) | 46 299 $ | 31.03.2024 |
Aktive Positionen von Utpal Koppikar
| Unternehmen | Position | Beginn |
|---|---|---|
| C4 THERAPEUTICS, INC. | Director/Board Member | 16.03.2022 |
Ehemalige bekannte Positionen von Utpal Koppikar
| Unternehmen | Position | Ende |
|---|---|---|
| ATARA BIOTHERAPEUTICS, INC. | Director of Finance/CFO | 31.03.2023 |
| FLEXION THERAPEUTICS, INC. | Director/Board Member | 19.11.2021 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01.06.2018 |
Ausbildung von Utpal Koppikar
| Stanford University | Graduate Degree |
| University of Maryland | Undergraduate Degree |
| UCLA Anderson School of Management | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| C4 THERAPEUTICS, INC. | Health Technology |
| ATARA BIOTHERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Flexion Therapeutics, Inc.
 Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA. | Health Technology |
